X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (129) 129
index medicus (93) 93
hematology (90) 90
male (89) 89
female (84) 84
middle aged (77) 77
aged (69) 69
oncology (69) 69
adult (52) 52
prognosis (34) 34
animals (27) 27
cancer (27) 27
aged, 80 and over (26) 26
survival (26) 26
medicine & public health (23) 23
mice (23) 23
leukemia (21) 21
leukemia, lymphocytic, chronic, b-cell - genetics (21) 21
treatment outcome (20) 20
disease progression (19) 19
retrospective studies (19) 19
chemotherapy (18) 18
lymphomas (18) 18
mutation (18) 18
analysis (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
cd38 expression (17) 17
therapy (16) 16
expression (15) 15
transplantation (15) 15
chronic lymphocytic leukemia (14) 14
young adult (14) 14
disease-free survival (13) 13
hemic and lymphatic diseases (13) 13
rituximab (13) 13
cell biology (12) 12
disease (12) 12
genotype (12) 12
leukemia, lymphocytic, chronic, b-cell - mortality (12) 12
leukemia, lymphocytic, chronic, b-cell - pathology (12) 12
patients (12) 12
survival analysis (12) 12
time factors (12) 12
adolescent (11) 11
apoptosis (11) 11
care and treatment (11) 11
cohort studies (11) 11
differentiation (11) 11
dna-binding proteins - genetics (11) 11
flow cytometry (11) 11
gene expression (11) 11
genes (11) 11
research (11) 11
activation (10) 10
anemia (10) 10
cell proliferation (10) 10
genetic aspects (10) 10
genomic aberrations (10) 10
hematology, oncology and palliative medicine (10) 10
hematopoietic stem cells (10) 10
stem cells (10) 10
survival rate (10) 10
t cells (10) 10
abridged index medicus (9) 9
cll (9) 9
eculizumab (9) 9
further section · weitere sektionen (9) 9
gene (9) 9
gene-expression (9) 9
leukemia, lymphocytic, chronic, b-cell - metabolism (9) 9
polymorphism, single nucleotide (9) 9
remission induction (9) 9
risk factors (9) 9
stem cell transplantation (9) 9
transcription factors - genetics (9) 9
antineoplastic agents - therapeutic use (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
b-cell lymphoma (8) 8
b-cells (8) 8
bone marrow - pathology (8) 8
cells, cultured (8) 8
clinical trials (8) 8
development and progression (8) 8
diagnosis (8) 8
follow-up studies (8) 8
health aspects (8) 8
lymphoma (8) 8
neutropenia (8) 8
prognostic marker (8) 8
zap-70 expression (8) 8
acute myeloid-leukemia (7) 7
alleles (7) 7
antibodies, monoclonal - therapeutic use (7) 7
antibodies, monoclonal, humanized (7) 7
article (7) 7
cells (7) 7
dna-binding proteins - metabolism (7) 7
gene expression regulation, leukemic (7) 7
genetics (7) 7
hematopoietic stem-cells (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4462 - 4469
Journal Article
Journal Article
Journal Article
Vaccine, ISSN 0264-410X, 10/2019, Volume 37, Issue 44, pp. 6682 - 6687
Cold agglutinin disease (CAD) is a rare, potentially life-threatening acquired autoimmune hemolytic anemia characterized by hemagglutination and hemolysis due... 
Eculizumab | Cold agglutinin disease (CAD) | N. meningitidis | Hemolysis | Antigens | Cold agglutinin disease | Conjugates | Cold | Anemia | Vaccination | Complement | Vaccines | Patients | Blood | Streptococcus infections | Hemagglutination | Complement activation | Hemolytic anemia | Autoimmune hemolytic anemia | Asplenia
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 03/2012, Volume 20, Issue 3, pp. 647 - 652
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 07/2017, Volume 15, Issue 1, pp. 158 - 15
Changes in glucose and energy metabolism contribute to the altered phenotype of cancer cells and are the basis for positron emission tomography with... 
Glucose metabolism | F-fluoro-2-deoxy-d-glucose | Lymphoma | 2-deoxy-d-glucose | Warburg effect | Cell Survival - drug effects | Humans | Fluorodeoxyglucose F18 - metabolism | Morpholines - pharmacology | Phosphatidylinositol 3-Kinases - metabolism | Glycolysis - drug effects | Proto-Oncogene Proteins c-myc - metabolism | Sirolimus - pharmacology | Lymphoma - metabolism | Time Factors | Cell Line, Tumor | Glucose - metabolism | Inhibitory Concentration 50 | Chromones - pharmacology | Care and treatment | Physiological aspects | Development and progression | Lymphomas | Cellular signal transduction | Glucose | Health aspects | Dextrose | TOR protein | Cell proliferation | Biotechnology | Energy metabolism | Transcription factors | Genes | c-Myc protein | Myc protein | Kinases | Cancer therapies | Proteins | Synergistic effects | Signal transduction | Pathways | Inhibition | Glucose transporter | Cell survival | Incubation | MiRNA | Positron emission | MAP kinase | Lactate dehydrogenase | Rapamycin | Tumor cell lines | Metabolism | Gene expression | Hexokinase | L-Lactate dehydrogenase | 1-Phosphatidylinositol 3-kinase | Polymerase chain reaction | Signaling | Inhibitors | Glycolysis | Hypoxia | Lactic acid | Glucose-6-phosphatase | Positron emission tomography | Viability | Transporter | Tumors | Cancer | 18F-fluoro-2-deoxy-d-glucose
Journal Article
Der Onkologe, ISSN 0947-8965, 10/2019, Volume 25, Issue 10, pp. 867 - 879
Journal Article
Cancer, ISSN 0008-543X, 03/2017, Volume 123, Issue 5, pp. 814 - 823
BACKGROUND Human leukocyte antigen‐E (HLA‐E) is a nonclassical major histocompatibility complex class I molecule that recently came into sharper focus as a... 
immune escape | chronic lymphocytic leukemia (CLL) | natural killer (NK) cells | human leukocyte antigen‐E (HLA‐E) | human leukocyte antigen-E (HLA-E) | NATURAL-KILLER-CELLS | UNTRANSLATED REGIONS | SURFACE EXPRESSION | POLYMORPHISM | CANCER | CD8(+) T-CELLS | NK CELLS | ONCOLOGY | LEUKOCYTE ANTIGEN-E | STEM-CELL TRANSPLANTATION | ASSOCIATION | Histocompatibility Antigens Class I - blood | Leukocytes - pathology | Prognosis | Humans | Middle Aged | Genotype | Male | Histocompatibility Antigens Class I - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Disease Progression | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Biomarkers, Tumor - blood | Alleles | Female | Leukemia, Lymphocytic, Chronic, B-Cell - blood | Aged | Usage | Chronic lymphocytic leukemia | Care and treatment | Histocompatibility antigens | HLA histocompatibility antigens | Development and progression | Research | Biological markers | Lymphocyte receptors | Antigens | Chronic lymphatic leukemia | Tumor cells | Leukemia | Transforming growth factor-b | Lymphatic leukemia | Multivariate analysis | Patients | Microspheres | Major histocompatibility complex | Degranulation | Biomarkers | Plasma levels | Histocompatibility antigen HLA | Interferon | Natural killer cells | Solid tumors | In vitro methods and tests | Histocompatibility | Tumors | Cancer
Journal Article
Genes, Chromosomes and Cancer, ISSN 1045-2257, 04/2014, Volume 53, Issue 4, pp. 309 - 316
T‐cell prolymphocytic leukemia (T‐PLL) is an aggressive post‐thymic T‐cell malignancy characterized by the recurrent inv(14)(q11q32)/t(14;14)(q11;q32) or... 
ACTIVATION | DOMAIN | GENE | ONCOLOGY | EXPRESSION | GENETICS & HEREDITY | Amino Acid Sequence | Humans | Janus Kinase 3 - genetics | Leukemia, Prolymphocytic, T-Cell - genetics | Molecular Sequence Data | Female | Male | Aged | Mutation | Chromosomes, Human, Pair 14 - genetics | Cohort Studies | T cells | Leukemia | Genetic aspects
Journal Article